TG Therapeutics, Inc.
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), anā¦ read more
Healthcare
Biotechnology
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$36.64
Price-2.06%
-$0.77
1Y
Price
Market Cap
$5.609b
Mid
Price/Earnings 3y Avg5y Avg
12.8x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+17.0%
EBITDA Margin+9.7%
Net Profit Margin-8.8%
Free Cash Flow Margin+17.0%
EBITDA Margin+9.7%
Net Profit Margin-8.8%
Free Cash Flow MarginRevenue
$700.349m
+13.6%
1y CAGR+47.3%
3y CAGR+2108.0%
5y CAGREarnings
$461.896m
+3.3%
1y CAGR+633.4%
3y CAGR+501.5%
5y CAGREPS
$2.86
+3.3%
1y CAGR+605.5%
3y CAGR+480.7%
5y CAGRBook Value
$583.131m
$1.529b
Assets$945.706m
Liabilities$753.557m
DebtDebt to Assets
49.3%
4.8x
Debt to EBITDAFree Cash Flow
-$14.191m
+43.2%
1y CAGR+17.5%
3y CAGR+33.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company